Form 4: Pharvaris CMO Executes Scheduled Stock Option Sales

Chief Medical Officer Peng Lu exercised and sold 18,733 shares of Pharvaris common stock under a pre-arranged 10b5-1 trading plan.

Summary

• Chief Medical Officer Peng Lu exercised options for 18,733 shares of Pharvaris N.V. (PHVS) at an exercise price of $2.59 per share.
• The shares were sold in two tranches on April 29 and April 30, 2026, at weighted average prices of $30.06 and $30.24, respectively.
• Transactions were conducted pursuant to a Rule 10b5-1 trading plan, which allows insiders to set up a predetermined schedule for selling stock.
• Following these transactions, the reporting person retains beneficial ownership of 66,083 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transactions were executed under a pre-planned 10b5-1 arrangement and represent standard executive compensation management.

Positives

• The transactions were executed under a pre-established 10b5-1 plan, indicating the sales were planned in advance rather than based on non-public information.
• The executive maintains a significant remaining equity stake in the company.

Negatives

• The sale represents a reduction in the direct equity holdings of a key member of the executive leadership team.

Risks

• Insider selling can sometimes be perceived by the market as a lack of confidence in future growth, though this was a scheduled 10b5-1 transaction.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that routine 10b5-1 sales by C-suite executives in the biotechnology sector are standard practice for liquidity and diversification and generally do not signal a change in corporate strategy.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for biotech executives to manage equity compensation while avoiding potential insider trading allegations.

Stakeholder Impact

• Shareholders should note the reduction in insider ownership, though the use of a 10b5-1 plan mitigates concerns regarding market timing.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Pharvaris, PHVS, Insider Trading, Form 4, Chief Medical Officer, 10b5-1